List of Nexiclon Xr drug patents
Nexiclon Xr is owned by Athena.
Nexiclon Xr contains Clonidine.
Nexiclon Xr has a total of 2 drug patents out of which 0 drug patents have expired.
Nexiclon Xr was authorised for market use on 03 December, 2009.
Nexiclon Xr is available in tablet, extended release;oral dosage forms.
The generics of Nexiclon Xr are possible to be released after 08 September, 2031.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8337890 | ATHENA | Modified release formulations containing drug-ion exchange resin complexes |
Apr, 2027
(4 years from now) | |
| US8623409 | ATHENA | Clonidine formulation |
Sep, 2031
(8 years from now) | |
Drugs and Companies using CLONIDINE ingredient
Market Authorisation Date: 03 December, 2009
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic